{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:19:55Z","timestamp":1788808795128,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jns.2024.123132","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T19:46:17Z","timestamp":1720640777000},"page":"123132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database"],"prefix":"10.1016","volume":"463","author":[{"given":"Victoria","family":"Nikitina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Santi Laurini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Montanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Motola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123132_bb0005","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jns.2024.123132_bb0010","author":"Multiple Sclerosis International Federation"},{"issue":"7","key":"10.1016\/j.jns.2024.123132_bb0015","doi-asserted-by":"crossref","first-page":"E1520","DOI":"10.1073\/pnas.1710401115","article-title":"Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility","volume":"115","author":"Russi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.jns.2024.123132_bb0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1352458517737394","article-title":"Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression","volume":"24","author":"Voskuhl","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2024.123132_bb0025","author":"National Multiple Sclerosis Multiple Society"},{"key":"10.1016\/j.jns.2024.123132_bb0030","author":"Gilenya \u00ae, INN-fingolimod- European Medicines Agency"},{"issue":"5","key":"10.1016\/j.jns.2024.123132_bb0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2024.123132_bb0040","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2024.123132_bb0045","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"15","key":"10.1016\/j.jns.2024.123132_bb0050","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","article-title":"Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2024.123132_bb0055","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","article-title":"Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study","volume":"87","author":"Cohen","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"16 Suppl","key":"10.1016\/j.jns.2024.123132_bb0060","doi-asserted-by":"crossref","first-page":"6, 332","DOI":"10.1212\/WNL.88.16_supplement.P6.332","article-title":"Early fingolimod treatment improves disease outcomes at 2 and 4 years in patients with relapsing-remitting multiple sclerosis","volume":"88","author":"Hohlfeld","year":"2017","journal-title":"Neurology"},{"issue":"16 Suppl","key":"10.1016\/j.jns.2024.123132_bb0065","first-page":"4, 409","article-title":"Radiological evidence of the long-term effect of fingolimod treatment in patients with relapsing-remitting multiple sclerosis","volume":"88","author":"Cohen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123132_bb0070","first-page":"390","article-title":"Early switch to fingolimod for achieving no evidence of multiple sclerosis disease activity: 8-year analysis of data from the TRANSFORMS study","volume":"88(16 Suppl):4","author":"Cohen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123132_bb0080","author":"The European Medicines Agency"},{"key":"10.1016\/j.jns.2024.123132_bb0090","unstructured":"European medicines agency - human medicines division. Important medical event terms list (MedDRA version 26.1). EMA\/431465\/2023 25\/09\/2023. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/meddra-important-medical-event-terms-list-version-261_en.xlsx."},{"key":"10.1016\/j.jns.2024.123132_bb0105","author":"National Multiple Sclerosis Multiple Society"},{"key":"10.1016\/j.jns.2024.123132_bb0110","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","article-title":"Comparative safety of high-efficacy disease-modifying therapies in relapsing\u2013remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"43","author":"\u015aladowska","year":"2022","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2024.123132_bb0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaneurol.2020.2950","article-title":"Efficacy and safety of 2 Fingolimod doses vs Glatiramer acetate for the treatment of patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"78","author":"Cree","year":"2021","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123132_bb0120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","article-title":"A systematic review and mixed treatment comparison of pharmaceutical interventions neurological sciences (2022) 43:5479\u20135500 5497 1 3 for multiple sclerosis","volume":"9","author":"Giovannoni","year":"2020","journal-title":"Neurol Ther"},{"issue":"10023","key":"10.1016\/j.jns.2024.123132_bb0125","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jns.2024.123132_bb0130","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bcp.14198","article-title":"The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: a meta-analysis","volume":"86","author":"Yang","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.jns.2024.123132_bb0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000320245","article-title":"Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study","volume":"35","author":"Christiansen","year":"2010","journal-title":"Neuroepidemiology"},{"issue":"15","key":"10.1016\/j.jns.2024.123132_bb0140","article-title":"S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review","volume":"22","author":"Constantinescu","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.jns.2024.123132_bb0145","first-page":"335","article-title":"Placebo-controlled study of theeffects offingolimod on cardiac rate and rhythm and pulmonaryfunction in healthy volunteers.Eur","volume":"68","author":"Schmouder","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.jns.2024.123132_bb0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00415-013-7115-8","article-title":"Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study","volume":"261","author":"Gold","year":"2014","journal-title":"J. Neurol."},{"issue":"3 Suppl","key":"10.1016\/j.jns.2024.123132_bb0155","first-page":"P764","article-title":"First dose effects of fingolimod: final results of an in-depth ECG and Holter study in 6,998 German RRMS patients","volume":"23","author":"Limmroth","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2024.123132_bb0160","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/389360","article-title":"Fingolimod real world experience: efficacy and safety in clinical practice","volume":"2015","author":"Fonseca","year":"2015","journal-title":"Neurosci J."},{"issue":"4","key":"10.1016\/j.jns.2024.123132_bb0165","first-page":"95","article-title":"Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1","volume":"11","author":"Rafiee Zadeh","year":"2019","journal-title":"Int J Physiol Pathophysiol Pharmacol."},{"issue":"4","key":"10.1016\/j.jns.2024.123132_bb0170","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","article-title":"Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings","volume":"3","author":"Kappos","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.jns.2024.123132_bb0175","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.msard.2014.05.005","article-title":"First-dose effects of fingolimod: pooled safety data from three phase 3 studies","volume":"3","author":"DiMarco","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.jns.2024.123132_bb0180","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","article-title":"Fingolimod-associated macular edema: incidence, detection, and management","volume":"78","author":"Jain","year":"2012","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2024.123132_bb0185","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/DHPS.S69640","article-title":"Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis","volume":"11","author":"Gajofatto","year":"2015","journal-title":"Drug Healthc Patient Saf."},{"issue":"7","key":"10.1016\/j.jns.2024.123132_bb0190","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ophtha.2012.12.040","article-title":"Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis","volume":"120","author":"Zarbin","year":"2013","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jns.2024.123132_bb0195","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1212\/WNL.0b013e31821043b5","article-title":"Primary varicella zoster infection associated with fingolimod treatment","volume":"76","author":"Uccelli","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2024.123132_bb0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10072-016-2701-z","article-title":"Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy","volume":"38","author":"Laroni","year":"2017","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123132_bb0205","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40264-014-0240-1","article-title":"A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee","volume":"37","author":"Pacurariu","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.jns.2024.123132_bb0210","article-title":"Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies","volume":"356","author":"Spelsberg","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2024.123132_bb0215","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40264-016-0491-0","article-title":"Evaluation of Facebook and twitter monitoring to detect safety signals for medical products: an analysis of recent FDA safety alerts","volume":"40","author":"Pierce","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.jns.2024.123132_bb0220","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-3-642-20195-0_17","article-title":"Postmarketing surveillance","volume":"205","author":"Vlahovi\u2019c-Pal\u02c7cevski","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jns.2024.123132_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"AlOmar","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.jns.2024.123132_bb0230","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2125.2005.02504.x","article-title":"Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital","volume":"60","author":"Vallano","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2024.123132_bb0235","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0895-4356(02)00450-X","article-title":"Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions","volume":"55","author":"Hasford","year":"2002","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jns.2024.123132_bb0240","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1590\/S0080-623420140000400023","article-title":"Causes for the underreporting of adverse drug events by health professionals: a systematic review","volume":"48","author":"Varallo","year":"2014","journal-title":"Rev. Esc. Enferm. USP"},{"issue":"6","key":"10.1016\/j.jns.2024.123132_bb0245","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.msard.2014.09.184","article-title":"Long-term safety of fingolimod: interim evaluation of data from the longterms trial","volume":"3","author":"Rosenstiel","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Suppl. 16","key":"10.1016\/j.jns.2024.123132_bb0250","doi-asserted-by":"crossref","first-page":"P5.365","DOI":"10.1212\/WNL.88.16_supplement.P5.365","article-title":"5 years safety of fingolimod in real world: first results from PANGAEA, a non-interventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practice","volume":"88","author":"Ziemssen","year":"2017","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:47:28Z","timestamp":1761785248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24002673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":46,"alternative-id":["S0022510X24002673"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123132","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123132"}}